201 related articles for article (PubMed ID: 38244525)
21. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis.
Burt RK; Han X; Quigley K; Helenowski IB; Balabanov R
J Neurol; 2022 May; 269(5):2513-2526. PubMed ID: 34633525
[TBL] [Abstract][Full Text] [Related]
22. A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views.
Ziemssen T; Tolley C; Bennett B; Kilgariff S; Jones E; Pike J; Tomic D; Piani-Meier D; Lahoz R
Mult Scler Relat Disord; 2020 Feb; 38():101861. PubMed ID: 31865132
[TBL] [Abstract][Full Text] [Related]
23. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
[No Abstract] [Full Text] [Related]
24. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
25. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
26. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
27. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
[No Abstract] [Full Text] [Related]
28. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
29. Clinical and demographic characteristics of late-onset multiple sclerosis: LOMS-TR study.
Sıvacı AÖ; Seferoğlu M; Piri Çınar B; Uzunköprü C; Beckmann Y; Güngör Doğan İ; Çetinkaya Tezer D; Tunç A; Ethemoğlu Ö; Gümüş H; Açıkgöz M; Yalaz Tekan Ü; Demir S
Mult Scler Relat Disord; 2024 Apr; 84():105469. PubMed ID: 38341979
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
31. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of humoral immunity, iron homeostasis, and lipid metabolism is associated with multiple sclerosis progression.
Wang Q; Wu Q; Yang J; Saad A; Mills E; Dowling C; Lundy S; Mao-Draayer Y
Mult Scler Relat Disord; 2023 Nov; 79():105020. PubMed ID: 37806231
[TBL] [Abstract][Full Text] [Related]
33. High temperature requirement A1 and macrophage migration inhibitory factor in the cerebrospinal fluid; a potential marker of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
Hjæresen S; Benedikz E; Sejbaek T; Axelsson M; Novakova L; Zhang M; Lycke J; Illes Z; Fex-Svenningsen Å
J Neurol Sci; 2024 Feb; 457():122888. PubMed ID: 38278096
[TBL] [Abstract][Full Text] [Related]
34. The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe.
Nicholas R; Rodgers J; Witts J; Lerede A; Friede T; Hillert J; Forsberg L; Glaser A; Manouchehrinia A; Ramanujam R; Spelman T; Klyve P; Drahota J; Horakova D; Joensen H; Pontieri L; Magyari M; Ellenberger D; Stahmann A; Butzkueven H; Van Der Walt A; Bezlyak V; Lines C; Middleton R
Ther Adv Neurol Disord; 2023; 16():17562864231198963. PubMed ID: 37771841
[TBL] [Abstract][Full Text] [Related]
35. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
36. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
[TBL] [Abstract][Full Text] [Related]
38. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
[TBL] [Abstract][Full Text] [Related]
40. Influence of Cardiovascular Risk Factors in Early Relapsing-Remitting Multiple Sclerosis: A Retrospective Analysis.
Arroyo-Pereiro P; Muñoz-Vendrell A; Bau L; Matas E; Romero-Pinel L; Martínez-Yélamos A; Martínez-Yélamos S
Eur Neurol; 2023; 86(1):73-77. PubMed ID: 36470228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
